In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The acquisition, announced in February, underscores Novo Nordisk’s push to boost output of its popular obesity drug Wegovy.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

also known as Mounjaro — that so far has shown even more weight loss than Wegovy. A pack of other companies are hot on both ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...